

- 1) **Association of VEGF-A Splice Variant mRNA Expression With Outcome in Bevacizumab-Treated Patients With Metastatic Breast Cancer.** *Clin Breast Cancer.* 2014 Oct;14(5):330-8. (<http://www.ncbi.nlm.nih.gov/pubmed/24703319>)
- 2) **Dose-dense sequential adjuvant chemotherapy followed, as indicated, by trastuzumab for one year in patients with early breast cancer: first report at 5-year median follow-up of a Hellenic Cooperative Oncology Group randomized phase III trial.** *BMC Cancer.* 2014 Jul 15;14:515. (<http://www.ncbi.nlm.nih.gov/pubmed/25026897> )
- 3) **Vascular endothelial growth factor polymorphisms and clinical outcome in patients with metastatic breast cancer treated with weekly docetaxel.** *Pharmacogenomics J.* 2014 Jun;14(3):248-55. (<http://www.ncbi.nlm.nih.gov/pubmed/24061601>)
- 4) **EGFR gene gain and PTEN protein expression are favorable prognostic factors in patients with KRAS wild-type metastatic colorectal cancer treated with cetuximab.** *J Cancer Res Clin Oncol.* 2014 May;140(5):737-48. (<http://www.ncbi.nlm.nih.gov/pubmed/24595598> )
- 5) **A study of gene expression markers for predictive significance for bevacizumab benefit in patients with metastatic colon cancer: a translational research study of the Hellenic Cooperative Oncology Group (HeCOG).** *BMC Cancer.* 2014 Feb 20;14:111. (<http://www.ncbi.nlm.nih.gov/pubmed/24555920>)
- 6) **Tecemotide (L-BLP25) versus placebo after chemoradiotherapy for stage III non-small-cell lung cancer (START): a randomised, double-blind, phase 3 trial.** *Lancet Oncol.* 2014 Jan;15(1):59-68. (<http://www.ncbi.nlm.nih.gov/pubmed/24331154>)
- 7) **The prognostic role of ephrin A2 and endothelial growth factor receptor pathway mediators in patients with advanced colorectal cancer treated with cetuximab.** *Clin Colorectal Cancer.* 2013 Dec;12(4):267-274.e2. (<http://www.ncbi.nlm.nih.gov/pubmed/24050852>)
- 8) **Cancer-related neuropathic pain in out-patient oncology clinics: a European survey.** *BMC Palliat Care.* 2013 Nov 7;12(1):41. (<http://www.ncbi.nlm.nih.gov/pubmed/24200014>)
- 9) **Ixabepilone administered weekly or every three weeks in HER2-negative metastatic breast cancer patients; a randomized non-comparative phase II trial.** *PLoS One.* 2013 Jul 23;8(7):e69256. (<http://www.ncbi.nlm.nih.gov/pubmed/23935969>)
- 10) **Prognostic significance of ESR1 gene amplification, mRNA/protein expression and functional profiles in high-risk early breast cancer: a translational study of the Hellenic Cooperative Oncology Group (HeCOG).** *PLoS One.* 2013 Jul 29;8(7):e70634. (<http://www.ncbi.nlm.nih.gov/pubmed/23923010>)

- 11) **Dose selection trial of metronomic oral vinorelbine monotherapy in patients with metastatic cancer: A Hellenic Cooperative Oncology Group clinical translational study.** BMC Cancer. 2013 May 29;13:263.  
(<http://www.ncbi.nlm.nih.gov/pubmed/23718900>)
- 12) **Prospective, open-label, randomized, phase III study of two dose-dense regimens MVAC versus gemcitabine/cisplatin in patients with inoperable, metastatic or relapsed urothelial cancer: a Hellenic Cooperative Oncology Group study (HE 16/03).** Ann Oncol. 2013 Apr;24(4):1011-7.  
(<http://www.ncbi.nlm.nih.gov/pubmed/23136231>)
- 13) **Evaluation of the prognostic role of centromere 17 gain and HER2/topoisomerase II alpha gene status and protein expression in patients with breast cancer treated with anthracycline-containing adjuvant chemotherapy: pooled analysis of two Hellenic Cooperative Oncology Group (HeCOG) phase III trials.** BMC Cancer. 2013 Mar 28;13:163. (<http://www.ncbi.nlm.nih.gov/pubmed/23537287>)
- 14) **Biomarkers of benefit from cetuximab-based therapy in metastatic colorectal cancer: interaction of EGFR ligand expression with RAS/RAF, PIK3CA genotypes.** BMC Cancer. 2013 Feb 2;13:49. (<http://www.ncbi.nlm.nih.gov/pubmed/23374602>)
- 15) **Expression profiling of 21 biomolecules in locally advanced nasopharyngeal carcinomas of Caucasian patients.** BMC Clin Pathol. 2013 Jan 29;13:1.  
(<http://www.ncbi.nlm.nih.gov/pubmed/23360534>)
- 16) **Aims, design and methods of a case-control study for the assessment of the role of dietary habits, eating behaviors and environmental factors, on the development of breast cancer.** Maturitas. 2013 Jan;74(1):31-6.  
(<http://www.ncbi.nlm.nih.gov/pubmed/23131812>)
- 17) **Prognostic significance of RACGAP1 mRNA expression in high-risk early breast cancer: a study in primary tumors of breast cancer patients participating in a randomized Hellenic Cooperative Oncology Group trial.** Cancer Chemother Pharmacol. 2013 Jan;71(1):245-55.  
(<http://www.ncbi.nlm.nih.gov/pubmed/23096218>)
- 18) **Pancreatic Adenocarcinoma Treatment Hellenic Oncology Survey 'PATHOS': Frequency and current treatment modalities of advanced pancreatic adenocarcinoma in Greece.** Forum of Clinical Oncology 2013; 4(Issue 4): 11-19 (πρωτότυπη δημοσίευση).
- 19) **Reintroduction of irinotecan and oxaliplatin as a combination (IROX regimen) in heavily pretreated colorectal cancer patients. A single-center experience.** Forum of Clinical Oncology 2013; 4(Issue 3): 13-18 (πρωτότυπη δημοσίευση).
- 20) **Colonic metastasis of renal cell carcinoma 4 months after left radical nephrectomy: A case report and review of post-nephrectomy colonic metastases from renal cell**

**carcinoma.** Forum of Clinical Oncology 2013; 4(Issue 2): 47-50 (δημοσίευση ενδιαφέροντος περιστατικού).

- 21) **Vascular endothelial growth factor polymorphisms and clinical outcome in colorectal cancer patients treated with irinotecan-based chemotherapy and bevacizumab.** Pharmacogenomics J. 2012 Dec;12(6):468-75.  
(<http://www.ncbi.nlm.nih.gov/pubmed/21844885>)
- 22) **The prognostic and predictive value of mRNA expression of vascular endothelial growth factor family members in breast cancer: a study in primary tumors of high-risk early breast cancer patients participating in a randomized Hellenic Cooperative Oncology Group trial.** Breast Cancer Res. 2012 Nov 12;14(6):R145.  
(<http://www.ncbi.nlm.nih.gov/pubmed/23146280>)
- 23) **Expression of angiogenic markers in the peripheral blood of patients with advanced breast cancer treated with weekly docetaxel.** Anticancer Res. 2012 Oct;32(10):4569-80. (<http://www.ncbi.nlm.nih.gov/pubmed/23060588>)
- 24) **Prevalence of BRCA1 mutations among 403 women with triple-negative breast cancer: implications for genetic screening selection criteria: a Hellenic Cooperative Oncology Group Study.** Breast Cancer Res Treat. 2012 Jul;134(1):353-62.  
(<http://www.ncbi.nlm.nih.gov/pubmed/22434525>)
- 25) **XELIRI-bevacizumab versus FOLFIRI-bevacizumab as first-line treatment in patients with metastatic colorectal cancer: a Hellenic Cooperative Oncology Group phase III trial with collateral biomarker analysis.** BMC Cancer. 2012 Jun 29;12:271.  
(<http://www.ncbi.nlm.nih.gov/pubmed/22748098>)
- 26) **Gemcitabine versus gemcitabine plus dalteparin thromboprophylaxis in pancreatic cancer.** Eur J Cancer. 2012 Jun;48(9):1283-92.  
(<http://www.ncbi.nlm.nih.gov/pubmed/22100906>)
- 27) **Carboplatin- or cisplatin-based chemotherapy in first-line treatment of small-cell lung cancer: the COCIS meta-analysis of individual patient data.** J Clin Oncol. 2012 May 10;30(14):1692-8. (<http://www.ncbi.nlm.nih.gov/pubmed/22473169>)
- 28) **Postoperative dose-dense sequential versus concomitant administration of epirubicin and paclitaxel in patients with node-positive breast cancer: 5-year results of the Hellenic Cooperative Oncology Group HE 10/00 phase III Trial.** Breast Cancer Res Treat. 2012 Apr;132(2):609-19.  
(<http://www.ncbi.nlm.nih.gov/pubmed/22187126>)
- 29) **An international expanded-access programme of everolimus: addressing safety and efficacy in patients with metastatic renal cell carcinoma who progress after initial vascular endothelial growth factor receptor-tyrosine kinase inhibitor therapy.** Eur J Cancer. 2012 Feb;48(3):324-32.  
(<http://www.ncbi.nlm.nih.gov/pubmed/21803569>)
- 30) **Induction chemotherapy followed by concomitant radiotherapy and weekly cisplatin versus the same concomitant chemoradiotherapy in patients with nasopharyngeal carcinoma: a randomized phase II study conducted by the Hellenic**

**Cooperative Oncology Group (HeCOG) with biomarker evaluation.** Ann Oncol. 2012 Feb;23(2):427-35. (<http://www.ncbi.nlm.nih.gov/pubmed/21525406>)

- 31) **Empirical therapy with ceftazidime combined with levofloxacin or once-daily amikacin for febrile neutropenia in patients with neoplasia: a prospective comparative study.** Eur J Clin Microbiol Infect Dis 2012; 31: 1389-1398 (πρωτότυπη δημοσίευση).
- 32) **Caspase 8 and caspase 9 gene polymorphisms and susceptibility to gastric cancer.** Gastric Cancer. 2011 Oct;14(4):317-21. (<http://www.ncbi.nlm.nih.gov/pubmed/21461653>)
- 33) **Paclitaxel and bevacizumab, as first line combined treatment, in patients with metastatic breast cancer.the hellenic cooperative oncology group experience with biological marker.** Anticancer Research 2011 Sep;31(9):3007-18
- 34) **Evaluation of the association of PIK3CA mutations and PTEN loss with efficacy of trastuzumab therapy in metastatic breast cancer.** Breast Cancer Res Treat. 2011 Jul;128(2):447-56. (<http://www.ncbi.nlm.nih.gov/pubmed/21594665>)
- 35) **Report of the long-term efficacy of two cycles of adjuvant bleomycin/ etoposide/ cisplatin in patients with stage I testicular nonseminomatous germ-cell tumors (nsgct): a risk adapted protocol of the hellenic cooperative oncology group.** Urologic Oncology 2011 Mar-Apr;29(2):189-93
- 36) **Paclitaxel and gemcitabine versus paclitaxel and vinorelbine in patients with advanced non-small-cell lung cancer. A phase III study of the Hellenic Cooperative Oncology Group (HeCOG).** Ann Oncol. 2011 Apr;22(4):827-34. (<http://www.ncbi.nlm.nih.gov/pubmed/20880999>)
- 37) **A randomized phase III trial of adjuvant chemotherapy with irinotecan, leucovorin and fluorouracil versus leucovorin and fluorouracil for stage II and III colon cancer: a Hellenic Cooperative Oncology Group study.** BMC Med. 2011 Jan 31;9:10. (<http://www.ncbi.nlm.nih.gov/pubmed/21281463>)
- 38) **Chemotherapy plus percutaneous radiofrequency ablation in patients with inoperable colorectal liver metastases.** WJGO 2011; 3: 60-66 (πρωτότυπη δημοσίευση).
- 39) **Irinotecan/fluorouracil/leucovorin or the same regimen followed by oxaliplatin/fluorouracil/leucovorin in metastatic colorectal cancer.** Anticancer Res. 2010 Oct;30(10):4325-33. (<http://www.ncbi.nlm.nih.gov/pubmed/21036759>)
- 40) **A randomised phase iii study of adjuvant platinum/docetaxel chemotherapy with or without radiation therapy in patients with gastric cancer.** Cancer Chemotherapy and Pharmacology 2010 May;65(6):1009-21
- 41) **Pulmonary Langerhans cell histiocytosis in a patient previously treated for germ cell tumor.** BUON. 2010 Jan-Mar;15(1):194-5. (<http://www.ncbi.nlm.nih.gov/pubmed/20414954>)

- 42) A randomized phase III study of adjuvant platinum/docetaxel chemotherapy with or without radiation therapy in patients with gastric cancer. *Cancer Chemother Pharmacol.* 2010 May;65(6):1009-21.  
(<http://www.ncbi.nlm.nih.gov/pubmed/20130877>)
- 43) A randomized phase II study of carboplatin plus pegylated liposomal doxorubicin versus carboplatin plus paclitaxel in platinum sensitive ovarian cancer patients: a hellenic cooperative oncology group study. *BMC Med* 2010 Jan 7;8:3.
- 44) The future in cancer treatment: Bevacizumab clinical trial program. *Forum of Clinical Oncology* 2010; Special Issue 1: 90-94 (άρθρο ανασκόπησης)
- 45) A randomized phase II study of carboplatin plus pegylated liposomal doxorubicin versus carboplatin plus paclitaxel in platinum sensitive ovarian cancer patients: a Hellenic Cooperative Oncology Group study. *Oncology*. 2009;77(2):107-12.  
(<http://www.ncbi.nlm.nih.gov/pubmed/20055981>)
- 46) Non small cell lung cancer in the elderly: clinico-pathologic, management and outcome characteristics in comparison to younger patients. *J Chemother.* 2009 Nov;21(5):573-83 (<http://www.ncbi.nlm.nih.gov/pubmed/19933050>)
- 47) Primary fallopian tube carcinoma: results of a retrospective analysis of 64 patients. *Gynecol Oncol* 2009 Oct;115(1):97-101
- 48) Randomized multicenter phase ii trial of cisplatin and ifosfamide with or without paclitaxel in recurrent or metastatic carcinoma of the uterine cervix: a hellenic cooperative oncology group (hecog) study. *Annals of Oncology* 2009 Aug;20(8):1362-8
- 49) Gene expression of estrogen receptor, progesterone receptor and microtubule-associated protein tau in high-risk early breast cancer: A quest for molecular predictors of treatment benefit in the context of a Hellenic cooperative oncology group trial. *Breast Cancer Research and Treatment* 2009 Jul;116(1):131-43
- 50) Stage I testicular seminoma: management and controversies. *Critical Reviews in Oncology/Hematology* 2009 Jul;71(1):22-8
- 51) Current management of stage I testicular non-seminomatous germ cell tumours. *Crit Rev Oncol Hematol* 2009 May;70(2):114-23
- 52) A randomized phase iii study comparing three anthracycline-free taxane-based regimens, as first line chemotherapy, in metastatic breast cancer: A Hellenic cooperative oncology group study. *Breast Cancer Research and Treatment* 2009 May;115(1):87-99
- 53) Pegfilgrastim administered on the same day with dose-dense adjuvant chemotherapy for breast cancer is associated with a higher incidence of febrile neutropenia as compared to conventional growth factor support: matched case-control study of the Hellenic Cooperative Oncology Group. *Oncology*. 2009;77(2):107-12. (<http://www.ncbi.nlm.nih.gov/pubmed/19622901>)

- 54) **Epithelial ovarian cancer in Greece: a retrospective study of 1,791 patients by the Hellenic Cooperative Oncology Group (HeCOG).** Anticancer Res. 2009 Feb;29(2):745-51. (<http://www.ncbi.nlm.nih.gov/pubmed/19331231>)
- 55) **Analysis of 7 immunohistochemical markers in male germ cell tumors demonstrates the prognostic significance of p53 and mib-1.** Anticancer Research 2009 Feb;29(2): 737-44
- 56) **Effects of epoetin-alpha on quality of life of cancer patients with solid tumors receiving chemotherapy.** Anticancer Res. 2009 Feb;29(2):693-702. (<http://www.ncbi.nlm.nih.gov/pubmed/19331224>)